CurrentBlue Cross Blue Shield - IowaPolicy 05.05.69

Miplyffa (arimoclomol) — coverage criteria for Niemann‑Pick disease type C

Policy governs prior authorization, coverage criteria, and dosing/quantity limits for Miplyffa (arimoclomol) used with miglustat to treat neurological manifestations of Niemann‑Pick disease type C in pediatric and adult members; applies to members whose benefits include the therapy and requires verification of member-specific benefits.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyMiplyffa (arimoclomol) — coverage criteria for Niemann‑Pick disease type C

Policy CodePolicy 05.05.69

Change TypeNo material changes

Effective DateMar 7, 2025

Next Review Date

Key ActionObtain prior authorization and submit genetic confirmation plus baseline NPCCSS and chart documentation to support initial or continuation approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 moAuth period

90/30dQty limit

2+ yrsFDA age

05.05.69Policy ID

Coverage Criteria for Miplyffa (arimoclomol)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial authorization

Authorization of 12 months may be granted for treatment when ALL of the following are met:

Initial approval criteria

Age: Member is 2 to 19 years of age.
Baseline assessment: Member has completed the NPC clinical severity scale (NPCCSS) assessment to establish baseline score.
Ambulation: Member is ambulatory (able to walk independently or with assistance).
Diagnostic confirmation (one of)
- Genetic confirmation: Genetically confirmed variant in both alleles of NPC1 or NPC2.
- Genetic plus laboratory/pathology: Mutation in only one allele of NPC1 or NPC2 plus either positive filipin staining or elevated cholestane-triol level (>2 times the upper limit of normal).
Clinical manifestations: Member has neurological manifestations of disease (e.g., loss of fine motor skills, swallowing, speech, ambulation).
Concomitant therapy: Requested medication will be used in combination with miglustat.
Therapy exclusivity: Requested medication will not be used in combination with Aqneursa (levacetylleucine) for NPC neurological treatment.

Continued treatment

Authorization of 12 months may be granted for continued treatment when ALL of the following are met:

Continuation approval criteria

Meet initial criteria: Member meets the criteria for initial approval.
Clinical benefit: Member is experiencing benefit from therapy (e.g., stabilization or improvement in 5-domain NPCCSS score, fine motor skills, swallowing, speech, ambulation).

Members who do not meet the specific clinical and documentation requirements outlined in this policy are considered not medically necessary for coverage of Miplyffa (arimoclomol).

Miplyffa (arimoclomol) is considered not medically necessary for members who do not meet the criteria set forth in this policy; members currently receiving samples or medication through a manufacturer patient assistance program must still meet the policy's initial approval criteria.

Prior Authorization, Documentation, and Provider Guidance

Prior Authorization

Prior authorization required

Prior authorization is required for initiation and continuation of therapy. Initial and continuation approvals may be granted for up to 12 months when all specified clinical criteria are met.

Authorization duration: up to 12 months
Age range for approval: 2–19 years (see clinical criteria)

Prior Authorization

Concomitant therapy constraints

The requested medication must be used in combination with miglustat and must not be used concurrently with Aqneursa (levacetylleucine) for treatment of neurological manifestations of Niemann-Pick disease type C.

Required concomitant therapy: miglustat
Prohibited combination: Aqneursa (levacetylleucine)

Documentation Required

Initial request documentation

Initial prior authorization requests must include documentation to confirm diagnosis and baseline disease status to begin review.

Genetic or molecular test results confirming diagnosis (NPC1 or NPC2 variants or alternative diagnostic confirmation).
Medical records/chart notes documenting neurological manifestations and ambulation status.
Baseline assessment documentation for the 5-domain NPC clinical severity scale (NPCCSS) to establish baseline score.

Documentation Required

Continuation request documentation

Continuation (reauthorization) requests must include clinical documentation demonstrating ongoing benefit from therapy.

Chart notes or medical records documenting positive clinical response such as stabilization or improvement in 5-domain NPCCSS score.
Documentation of stabilization or improvement in domains including fine motor skills, swallowing, speech, or ambulation.

Denial Risk

Denial if criteria not met

Treatment is considered not medically necessary and will be denied if the member does not meet the specified approval criteria. Members receiving medication as samples or through manufacturer patient assistance programs must still meet initial approval criteria.

Denial if member does not meet all required criteria for initial or continued approval
Samples or patient assistance program supply does not exempt member from meeting approval criteria

Definitions and Clinical Scales

5-domain NPCCSS

DefinitionNPC clinical severity scale used to establish baseline and to assess stabilization or improvement in neurological status (fine motor skills, swallowing, speech, ambulation).

Use at baselineBaseline NPCCSS assessment required to establish baseline score for initial authorization.

Use for continuationContinuation requests must document stabilization or improvement in 5-domain NPCCSS score to demonstrate clinical benefit.

DocumentationMedical records (chart notes) of the baseline assessment for the 5-domain NPCCSS must be submitted with initial requests.

Indication

FDA-approved indicationUse in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC).

Patient ageIndicated for adult and pediatric patients 2 years of age and older.

Treatment contextAuthorized therapy must be used in combination with miglustat and not used with Aqneursa (levacetylleucine) for NPC neurological treatment.